PPD DEVELOPMENT LP - FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASURE

PIID: 75F40124C00117

Signed Date: Oct 23, 2025Effective Date: Sep 11, 2024End Date: Closes in 64 days

Award $

$724K

Vendor

PPD DEVELOPMENT LP

NAICS

541714

Signed Date

Oct 23, 2025

Key Details

Dollars Obligated

$724,461

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

Food and Drug Administration

NAICS Code

541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

Product Service Code

B529 - SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA

Extent Competed

COMPETED UNDER SAP

Number of Offers

Place of Performance

WILMINGTON, NC, 284013331, CD-NC-07

Description

FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASURE

Context & Analysis

On Oct 23, 2025, Department of Health and Human Services obligated $724,461 to PPD DEVELOPMENT LP for fdabaa-24-00123, ref # fy24c1ep6, cardiovascular-kidney-metabolic (ckm) syndrome patient-reported outcome (pro) burden measure. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: competed under sap with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in WILMINGTON, NC. The contract is scheduled through Nov 15, 2026 — approximately 2 months remaining.